Full text is available at the source.
Abstract
Semaglutide and tirzepatide are increasingly prescribed to adults with type 2 diabetes undergoing total knee arthroplasty.
- There is uncertainty regarding differences in short-term postoperative outcomes between semaglutide and tirzepatide.
- Both medications target hormonal pathways that may influence metabolic responses.
- The increasing use of these agents in T2DM patients undergoing surgery highlights a potential area for further investigation.
Simplified